Welcome to LookChem.com Sign In|Join Free

CAS

  • or

137863-89-9

Post Buying Request

137863-89-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • N-[(2'-Cyano-(1,1'-biphenyl)-4-yl)methyl)]valine methyl ester Manufacturer/High quality/Best price/In stock

    Cas No: 137863-89-9

  • USD $ 1.0-3.0 / Metric Ton

  • 1 Metric Ton

  • 10 Metric Ton/Day

  • Hebei yanxi chemical co.,LTD.
  • Contact Supplier

137863-89-9 Usage

Uses

N-[(2'-Cyano[1,1'-biphenyl]-4-yl)methyl]-L-valine Methyl Ester is an intermediate in the preparation of angiotensin II type 1 receptor antagonists.

Check Digit Verification of cas no

The CAS Registry Mumber 137863-89-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,7,8,6 and 3 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 137863-89:
(8*1)+(7*3)+(6*7)+(5*8)+(4*6)+(3*3)+(2*8)+(1*9)=169
169 % 10 = 9
So 137863-89-9 is a valid CAS Registry Number.

137863-89-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-Methyl 2-(((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)amino)-3-methylbutanoate

1.2 Other means of identification

Product number -
Other names methyl (2S)-2-[[4-(2-cyanophenyl)phenyl]methylamino]-3-methylbutanoate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:137863-89-9 SDS

137863-89-9Relevant articles and documents

Readily Reconfigurable Continuous-Stirred Tank Photochemical Reactor Platform

Blacker, A. John,Francis, Daniel,Kapur, Nikil,Marsden, Stephen P.

, (2022/01/12)

A new modular photochemical continuous stirred-tank reactor (CSTR) design is described, based upon the development of light-source units that can be fitted to the previously described fReactor CSTR platform. In addition to use in homogeneous photochemical reactions (e.g., photoredox-catalyzed hydroamination), these units are especially well suited to handling multiphasic mixtures, exemplified here in solid-liquid (Wohl-Ziegler bromination) and gas-liquid (photocatalytic oxidative decarboxylation) reactions. The use of slurries as input feeds allows for the intensification of photochemical brominations, while the modular nature of the system facilitates the simple integration of downstream reaction steps, exemplified here in a continuous synthesis of an intermediate for the antihypertensive drug valsartan.

Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect

Nie, Yong-Yan,Da, Ya-Jing,Zheng, Hao,Yang, Xiao-Xia,Jia, Lin,Wen, Cai-Hong,Liang, Li-Sha,Tian, Juan,Chen, Zhi-Long

, p. 2747 - 2761 (2012/05/20)

A series of novel angiotensin II type 1 receptor antagonists were prepared. Radioligand binding assay suggested that compounds 1b and 1c could be recognized by the AT1 receptor with an IC50 value of 1.6 ± 0.09 nM and 2.64 ± 0.7 nM, respectively. In vivo anti-hypertension experiments showed that compounds (1a, 1b, 1c, 1e) elicited a significant decrease in SBP and DBP of spontaneous hypertensive rats (SHRs). The antihypertensive effects maintained for 10 h, which indicated that these compounds had a favorable blood pressure-lowering effect. Acute toxicity testing suggested that the LD50 value of compound 1b was 2316.8 mg/kg which was lower than valsartan (LD50 = 307.50 mg/kg) but higher than losartan (LD50 = 2248 mg/kg). So they could be considered as novel anti-hypertension candidates and deserved for further investigation.

AN IMPROVED PROCESS FOR THE PREPARATION OF VALSARTAN

-

Page/Page column 16, (2010/11/29)

The present invention relates to an improved process for the preparation of valsartan compound of formula-1 through novel intermediate compounds. It also relates to a novel process for the preparation of amorphous form of valsartan.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 137863-89-9